One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The use of patient-reported outcomes (PROs) in cancer care: a realistic strategy
E.Minvielle12M.di Palma1O.Mir1F.Scotté1
Improving access to immunotherapy in low- and middle-income countries
A.Patel1D.A.Goldstein24I.F.Tannock34
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
J.Oldenburg12D.M.Berney34C.Bokemeyer5M.A.Climent6G.Daugaard7J.A.Gietema8U.De Giorgi9H.S.Haugnes10R.A.Huddart11R.Leão12A.Sohaib13S.Gillessen141516T.Powles4ESMO Guidelines CommitteeEURACAN
External control arms in oncology: current use and future directions
P.S.Mishra-Kalyani1L.Amiri Kordestani2D.R.Rivera3H.Singh23A.Ibrahim2R.A.DeClaro23Y.Shen1S.Tang1R.Sridhara3P.G.Kluetz23J.Concato4R.Pazdur23J.A.Beaver23
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C.E.Geyer12W.M.Sikov3J.Huober4H.S.Rugo5N.Wolmark16J.O’Shaughnessy78D.Maag9M.Untch10M.Golshan11J. PonceLorenzo12O.Metzger13M.Dunbar9W.F.Symmans14P.Rastogi115J.H.Sohn16R.Young17G.S.Wright18C.Harkness19…S.Loibl2122
Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial
U.Pastorino1M.Boeri2S.Sestini1F.Sabia1G.Milanese13M.Silva3P.Suatoni1C.Verri2A.Cantarutti4N.Sverzellati3G.Corrao4A.Marchianò5G.Sozzi2
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
V.Subbiah1R.J.Kreitman2Z.A.Wainberg3J.Y.Cho4J.H.M.Schellens5J.C.Soria6P.Y.Wen7C.C.Zielinski8M.E.Cabanillas1A.Boran9P.Ilankumaran9P.Burgess10T.Romero Salas9B.Keam11
Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
A.Gazzah1P.L.Bedard2C.Hierro3Y.-K.Kang4A.Abdul Razak2M.-H.Ryu4B.Demers5N.Fagniez6C.Henry7M.Hospitel8J.-C.Soria9J.Tabernero310
Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing
P.Terraf1†F.Pareja1†D.N.Brown1O.Ceyhan-Birsoy1M.Misyura1S.Rana1E.O’Reilly2M.I.Carlo2C.Aghajanian2Y.Liu2F.Derakhshan1G.Jayakumaran1B.Weigelt1M.Walsh3Z.Stadler23K.Offit3M.Ladanyi1M.Robson2…D.Mandelker1
Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients
J.Chen1F.Facchinetti1F.Braye1A.A.Yurchenko1L.Bigot1S.Ponce12D.Planchard3A.Gazzah2S.Nikolaev14S.Michiels5D.Vasseur167L.Lacroix167L.Tselikas8C.Nobre1K.A.Olaussen1F.Andre134J.Y.Scoazec67F.Barlesi39…L.Friboulet1
Concomitant type 2 diabetes mellitus (T2DM) in metastatic melanoma patients could be related to lower level of LAG-3: a transcriptomic analysis of a retrospective cohort
D.Mallardo1A.Cortellini2M.Capone1G.Madonna1D.J.Pinato23S.Warren4E.Simeone1P.A.Ascierto1
VP2-2022: Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
I.B.Vergote1A. PérezFidalgo2E.Hamilton3G.Valabrega4T.Van Gorp5J.Sehouli6D.Cibula7T.Levy8S.Welch9D.L.Richardson10E.M. GuerraAlÃa11G.Scambia12S.Henry13P.Wimberger14D.Miller15J.MartÃnez16B.J.Monk17S.Shacham18…V.Makker20
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
L.Paz-Ares1M.E.R.O'Brien2M.Mauer3U.Dafni4K.Oselin5L.Havel6E.Esteban Gonzalez7D.Isla8A.Martinez-Marti9M.Faehling10M.Tsuboi11J-S.Lee12K.Nakagawa13J.Yang14S.M.Keller15N.Jha3S.I.Marreaud16R.A.Stahel17…B.Besse19
Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer�: [Annals of Oncology 33 (2022) 57-66]
S.Novello1V.Torri2C.Grohe3S.Kurz4M.Serke5T.Wehler5A.Meyer6D.Ladage6M.Geissler7I.Colantonio8C.Cauchi8E.Stoelben9A.Ceribelli10C.Kropf-Sanchen11G.Valmadre12G.Borra13M.Schena14A.Morabito15…G.V.Scagliotti1
Corrigendum to “589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)�: [Annals of Oncology 32 suppl. 5 (2021) S637-S638]
E.Perez-Navarro1V.Conteduca2A.González-del-Alba3B.Mellado4P.Cremaschi5O.Fernandez-Calvo6M.J.Méndez-Vidal7M.A.Climent8I.Duran9A.Font10M.P.Fernandez-Perez11A.MartÃnez12M.J.López-Andreo13G.Attard5D.Castellano1E.Grande14U.de Giorgi2J.A.Botia15…E.Gonzalez-Billalabeitia1
